Total Payments
$8,017
2024 Payments
$1,576
Companies
22
Transactions
231
Medicare Patients
371
Medicare Billing
$15,597
Payment Breakdown by Category
Food & Beverage$3,973 (49.6%)
Research$2,500 (31.2%)
Consulting$1,378 (17.2%)
Education$115.19 (1.4%)
Travel$51.36 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,973 | 223 | 49.6% |
| Unspecified | $2,500 | 1 | 31.2% |
| Consulting Fee | $1,378 | 1 | 17.2% |
| Education | $115.19 | 5 | 1.4% |
| Travel and Lodging | $51.36 | 1 | 0.6% |
Payments by Type
General
$5,517
230 transactions
Research
$2,500
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Promius Pharma LLC | $2,500 | 1 | $0 (2017) |
| Novo Nordisk Inc | $2,133 | 47 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,260 | 71 | $0 (2024) |
| GlaxoSmithKline, LLC. | $349.12 | 20 | $0 (2020) |
| Astellas Pharma US Inc | $290.08 | 12 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $261.05 | 9 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $196.90 | 9 | $0 (2019) |
| Allergan, Inc. | $193.94 | 12 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $149.88 | 11 | $0 (2020) |
| PFIZER INC. | $147.62 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,576 | 11 | Novo Nordisk Inc ($1,465) |
| 2023 | $80.21 | 5 | Novo Nordisk Inc ($48.77) |
| 2022 | $102.88 | 6 | Novo Nordisk Inc ($41.11) |
| 2021 | $260.46 | 16 | Novo Nordisk Inc ($113.52) |
| 2020 | $633.00 | 38 | AstraZeneca Pharmaceuticals LP ($257.01) |
| 2019 | $675.31 | 42 | AstraZeneca Pharmaceuticals LP ($252.60) |
| 2018 | $992.71 | 54 | AstraZeneca Pharmaceuticals LP ($277.02) |
| 2017 | $3,696 | 59 | Promius Pharma LLC ($2,500) |
All Payment Transactions
231 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,377.50 | General |
| 09/25/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $51.36 | General |
| 09/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.17 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/28/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Diabetes | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Respiratory | ||||||
| 02/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/30/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Respiratory | ||||||
| 09/01/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Diabetes | ||||||
| 07/28/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.06 | General |
| 06/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Diabetes | ||||||
| 01/23/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/28/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/15/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Diabetes | ||||||
| 06/17/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Diabetes | ||||||
| 04/08/2022 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/25/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Diabetes | ||||||
| 02/17/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: Diabetes | ||||||
| 10/20/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Diabetes | ||||||
| 10/16/2021 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DFD-06-CD-011 | Promius Pharma LLC | $2,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 29 | 47 | $3,990 | $2,186 |
| 2021 | 12 | 291 | 321 | $19,061 | $9,869 |
| 2020 | 3 | 51 | 105 | $8,650 | $3,542 |
Total Patients
371
Total Services
473
Medicare Billing
$15,597
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 32 | $3,840 | $2,141 | 55.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 11 | 15 | $150.00 | $44.64 | 29.8% |
| 0031A | Adm sarscov2 vac ad26 .5ml | Office | 2021 | 74 | 74 | $5,920 | $2,868 | 48.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 41 | $4,920 | $2,845 | 57.8% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 39 | 39 | $3,120 | $1,632 | 52.3% |
| 0034A | Fee covid-19 vac 4 res | Office | 2021 | 15 | 15 | $1,200 | $627.75 | 52.3% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 12 | 12 | $960.00 | $502.20 | 52.3% |
| 0013A | Fee covid-19 vac 2 booster | Office | 2021 | 12 | 12 | $960.00 | $502.20 | 52.3% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 11 | 11 | $880.00 | $460.35 | 52.3% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 11 | 11 | $880.00 | $364.59 | 41.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 15 | 22 | $220.00 | $66.00 | 30.0% |
| 91300 | Sarscov2 vac 30mcg/0.3ml im | Office | 2021 | 47 | 51 | $0.51 | $0.51 | 100.0% |
| 91301 | Sarscov2 vac 100mcg/0.5ml im | Office | 2021 | 18 | 19 | $0.19 | $0.19 | 100.0% |
| 91303 | Sarscov2 vac ad26 .5ml im | Office | 2021 | 14 | 14 | $0.14 | $0.14 | 100.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 56 | $6,720 | $2,900 | 43.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 13 | 18 | $1,620 | $549.48 | 33.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 17 | 31 | $310.00 | $92.28 | 29.8% |
About Dr. Eduardo Viera, MD
Dr. Eduardo Viera, MD is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144273426.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eduardo Viera, MD has received a total of $8,017 in payments from pharmaceutical and medical device companies, with $1,576 received in 2024. These payments were reported across 231 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($3,973).
As a Medicare-enrolled provider, Viera has provided services to 371 Medicare beneficiaries, totaling 473 services with total Medicare billing of $15,597. Data is available for 3 years (2020–2022), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Miami, FL
- Active Since 05/18/2006
- Last Updated 11/20/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144273426
Products in Payments
- FARXIGA (Drug) $579.67
- SYMBICORT (Drug) $515.06
- Ozempic (Drug) $487.24
- Trintellix (Drug) $214.38
- ANORO (Drug) $192.57
- MYRBETRIQ (Drug) $142.99
- TOUJEO (Drug) $136.06
- PRALUENT (Drug) $124.99
- ELIQUIS (Drug) $111.27
- Victoza (Drug) $83.73
- XARELTO (Drug) $75.58
- TRELEGY ELLIPTA (Drug) $75.30
- INVOKANA (Drug) $74.30
- ENTRESTO (Drug) $70.35
- NAMENDA XR (Drug) $68.26
- BEVESPI AEROSPHERE (Drug) $67.82
- XIFAXAN (Drug) $63.55
- TRULICITY (Drug) $56.39
- Aimovig (Biological) $55.53
- LYRICA (Drug) $54.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Internal Medicine $800,664
Mark Kutner, Md, MD
Internal Medicine — Payments: $610,516
Internal Medicine $610,516
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Internal Medicine $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Internal Medicine $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504
Internal Medicine $470,504